Needham Rates Neumora Therapeutics (NMRA) buy, $5 Price Target

Needham maintains its positive outlook on Neumora Therapeutics, setting a $5.00 price target, a 231.13% upside from the current price.

By EarningsIQ Research Desk · Published Jun 17, 2026, 2:02 AM EDT · Updated Jun 22, 2026, 2:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Needham rated Neumora Therapeutics, Inc. ($NMRA) "buy" with a $5 price target on June 16, 2026.

Since the rating, $NMRA is up 3.2% after 1 week, up 2.6% after 1 month and down 69.9% to date (from the $1.56 close on Jun 16, 2026).

NMRA Neumora Therapeutics, Inc.

$0.47 -71.69% year to date

Daily close · Oct 16, 2026

Key Points

Needham reiterated its buy rating on Neumora Therapeutics with a $5.00 price target on June 16, 2026.
Needham's $5 price target implies 231.13% upside from Neumora Therapeutics, Inc.'s ($NMRA) current $1.51 share price.
Neumora Therapeutics, traded as NMRA on NasdaqGS, has a market cap of $289 million and a 52-week range of $0.72 to $3.65.
Recent insider activity includes multiple purchases of 80,000 shares each by executives on May 27, 2026.

Get $NMRA trade alerts by text

We text you when insiders, Congress or big funds trade $NMRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Neumora Therapeutics, Inc. alert may contain errors. Disclosures

On June 16, 2026, Needham reiterated its buy rating for Neumora Therapeutics, Inc. (NasdaqGS: NMRA), setting a price target of $5.00. The analyst, Ami Fadia, continues to see potential in the company's pipeline of treatments for brain diseases and neuropsychiatric disorders.

Other Institutional Activity in Neumora Therapeutics

SIREN, L.L.C. significantly increased its holdings in Neumora, adding 2,209,039 shares to reach a total of 8,497,822 shares valued at about $16.57 million. SOFTBANK GROUP CORP. reduced its stake by 339,419 shares, ending with 6,090,301 shares worth approximately $11.88 million. Perceptive Advisors LLC initiated a position with 5,104,097 shares, valued at nearly $9.95 million. Meanwhile, MIC Capital Management UK LLP maintained its position, holding 4,460,700 shares valued at $8.70 million.

Neumora Therapeutics, Inc. Stock Up 106.8%

Shares of Neumora Therapeutics (NasdaqGS: NMRA) traded around $0.91. The company has a market cap of approximately $289 million and a beta of 2.759, indicating high volatility. The stock's 52-week range spans from $0.72 to $3.65, with a 50-day moving average of $1.95 and a 200-day moving average of $2.20. Neumora has a current ratio of 5.095 and a quick ratio of 4.884, with a debt-to-equity ratio of 75.514.

12-month forecast

$NMRA price target

Neumora Therapeutics, Inc. daily closes and this analyst's $5 target. Not advice.

Insider Buying and Selling at Neumora Therapeutics, Inc.

On May 27, 2026, several insiders at Neumora Therapeutics, including Matthew Fust, Maykin Ho, Kristina Burow, Alaa Halawa, and David Piacquad, each purchased 80,000 shares. These transactions were not part of any pre-planned trading program. Additionally, on February 17, 2026, Michael Lee Milligan, the Chief Financial Officer, sold 1,436 shares at an average price of $3.56.

Analysts Set New Price Targets

On June 16, 2026, Needham maintained its buy rating for Neumora Therapeutics with a $5.00 price target. The same day, HC Wainwright & Co. also maintained a buy rating, setting a higher target of $7.00. Overall, the consensus among analysts is a buy, with a mean price target of $8.91 based on eight analyst opinions.

About Neumora Therapeutics

Neumora Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, focused on developing treatments for brain-related diseases. The company's lead product, navacaprant (NMRA-140), is in phase 3 clinical trials for major depressive disorder. Neumora is also working on treatments for Alzheimer's-related agitation, schizophrenia, Parkinson's Disease, Amyotrophic Lateral Sclerosis, and obesity. Founded in 2019, the company is led by CEO Dr. Joshua Pinto and employs 92 people.

Bottom Line

Needham's reiterated buy rating and $5.00 price target underscore the firm's confidence in Neumora's therapeutic pipeline. With ongoing developments and a volatile trading history, Neumora remains a stock to watch. As always, remember that 13F filings and analyst ratings reflect past performance and expectations, not current conditions.